<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04247919</url>
  </required_header>
  <id_info>
    <org_study_id>C02-001 SC002</org_study_id>
    <nct_id>NCT04247919</nct_id>
  </id_info>
  <brief_title>DOAC ADRs Retrospective Study on Genetic Variations</brief_title>
  <acronym>DARES1</acronym>
  <official_title>Investigation of Genetic Variations on Patients With Adverse Drug Events While on Direct Oral Anticoagulants (DOACs)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cipherome, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Santa Clara Valley Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cipherome, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This retrospective study's objective is to evaluate if Cipherome's algorithm could have
      predicted the serious adverse drug reactions (ADRs) experienced by patients while on direct
      oral anti-coagulants (DOACs).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Using the latest next generation sequencing tools, this study will evaluate adverse drug
      reactions (ADRs) (e.g., major bleeding or treatment failure) in study participants while on
      direct oral anticoagulants (DOACs). A web-based program will analyze the data obtain from
      sequencing, and generate a drug safety score (DSS). The DSS risk score will be compared with
      pre-specified serious ADRs associated with DOAC therapy. A secondary analysis will involve
      discovery of novel variants that arise from our analysis and may potentially affect the
      outcome of DOAC treatment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 27, 2020</start_date>
  <completion_date type="Anticipated">May 29, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with a Major Bleeding Event</measure>
    <time_frame>Within 90 days of DOAC therapy initiation</time_frame>
    <description>Reduction in hemoglobin of at least 2 g/dL Blood loss requiring transfusion of at least 2 units of whole blood or erythrocytes Critical anatomical sites of bleeding: intramuscular with compartment syndrome, intracranial, intraspinal, retroperitoneal, intraocular, pericardial, and atraumatic intra-articular bleeding.
Bleeding led to death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with a Clinically Relevant Non-major Bleeding Event</measure>
    <time_frame>Within 90 days of DOAC therapy initiation</time_frame>
    <description>Acute or subacute clinically overt bleed that does not meet the criteria for a major bleed but prompts a clinical response, in that it leads to at least one of the following:
A hospital admission for bleeding, or A physician guided medical or surgical treatment for bleeding, or A change in antithrombotic therapy (including interruption or discontinuation of study drug).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Deaths Reported</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Death at any time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with a Thromboembolic Event</measure>
    <time_frame>Within 90 days of DOAC therapy initiation</time_frame>
    <description>Deep vein thrombosis, pulmonary embolism, ischemic stroke, transient ischemic attack, arterial thrombosis, or other thromboembolic event.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">17</enrollment>
  <condition>Drug-Related Side Effects and Adverse Reactions</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Study participants will either submit saliva samples or have a laboratory drawn blood sample.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients on rivaroxaban, apixaban, and dabigatran who experienced a serious adverse
        drug reaction and/or treatment failure.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any adult patient 18 years and older, who experienced a serious adverse drug reaction
             while taking a DOAC and is able to provide informed consent.

        Exclusion Criteria:

          -  Failure to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clifford Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Santa Clara Valley Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michelle Wilson, MD</last_name>
    <role>Study Director</role>
    <affiliation>Santa Clara Valley Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jessica Song, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Santa Clara Valley Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elijah Yi, BS</last_name>
    <phone>4082431460</phone>
    <phone_ext>1005</phone_ext>
    <email>elijah.yi@cipherome.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jane Chiang, MD</last_name>
    <phone>4082431460</phone>
    <phone_ext>1007</phone_ext>
    <email>jane.chiang@cipherome.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013 Oct 15;112(8):1142-7. doi: 10.1016/j.amjcard.2013.05.063. Epub 2013 Jul 4.</citation>
    <PMID>23831166</PMID>
  </reference>
  <reference>
    <citation>Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med. 2007 Jul 9;167(13):1414-9.</citation>
    <PMID>17620536</PMID>
  </reference>
  <reference>
    <citation>Zareh M, Davis A, Henderson S. Reversal of warfarin-induced hemorrhage in the emergency department. West J Emerg Med. 2011 Nov;12(4):386-92. doi: 10.5811/westjem.2011.3.2051.</citation>
    <PMID>22224125</PMID>
  </reference>
  <reference>
    <citation>Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes. 2012 Sep 1;5(5):615-21. Epub 2012 Sep 4.</citation>
    <PMID>22949490</PMID>
  </reference>
  <reference>
    <citation>Bauer KA. Pros and cons of new oral anticoagulants. Hematology Am Soc Hematol Educ Program. 2013;2013:464-70. doi: 10.1182/asheducation-2013.1.464. Review.</citation>
    <PMID>24319220</PMID>
  </reference>
  <reference>
    <citation>Kanuri SH, Kreutz RP. Pharmacogenomics of Novel Direct Oral Anticoagulants: Newly Identified Genes and Genetic Variants. J Pers Med. 2019 Jan 17;9(1). pii: E7. doi: 10.3390/jpm9010007. Review.</citation>
    <PMID>30658513</PMID>
  </reference>
  <reference>
    <citation>Sennesael AL, Larock AS, Douxfils J, Elens L, Stillemans G, Wiesen M, Taubert M, Dogn√© JM, Spinewine A, Mullier F. Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study. Thromb J. 2018 Nov 12;16:28. doi: 10.1186/s12959-018-0183-3. eCollection 2018.</citation>
    <PMID>30455596</PMID>
  </reference>
  <reference>
    <citation>Ing Lorenzini K, Daali Y, Fontana P, Desmeules J, Samer C. Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect. Front Pharmacol. 2016 Dec 19;7:494. doi: 10.3389/fphar.2016.00494. eCollection 2016.</citation>
    <PMID>28066243</PMID>
  </reference>
  <reference>
    <citation>Ueshima S, Hira D, Kimura Y, Fujii R, Tomitsuka C, Yamane T, Tabuchi Y, Ozawa T, Itoh H, Ohno S, Horie M, Terada T, Katsura T. Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation. Br J Clin Pharmacol. 2018 Jun;84(6):1301-1312. doi: 10.1111/bcp.13561. Epub 2018 Apr 16.</citation>
    <PMID>29457840</PMID>
  </reference>
  <reference>
    <citation>Shi J, Wang X, Nguyen JH, Bleske BE, Liang Y, Liu L, Zhu HJ. Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender. Biochem Pharmacol. 2016 Nov 1;119:76-84. doi: 10.1016/j.bcp.2016.09.003. Epub 2016 Sep 8.</citation>
    <PMID>27614009</PMID>
  </reference>
  <reference>
    <citation>Dimatteo C, D'Andrea G, Vecchione G, Paoletti O, Cappucci F, Tiscia GL, Buono M, Grandone E, Testa S, Margaglione M. Pharmacogenetics of dabigatran etexilate interindividual variability. Thromb Res. 2016 Aug;144:1-5. doi: 10.1016/j.thromres.2016.05.025. Epub 2016 May 26.</citation>
    <PMID>27261537</PMID>
  </reference>
  <reference>
    <citation>Sychev DA, Levanov AN, Shelekhova TV, Bochkov PO, Denisenko NP, Ryzhikova KA, Mirzaev KB, Grishina EA, Gavrilov MA, Ramenskaya GV, Kozlov AV, Bogoslovsky T. The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty. Pharmgenomics Pers Med. 2018 Jul 25;11:127-137. doi: 10.2147/PGPM.S169277. eCollection 2018. Erratum in: Pharmgenomics Pers Med. 2018 Sep 26;11:167.</citation>
    <PMID>30100750</PMID>
  </reference>
  <reference>
    <citation>1000 Genomes Project Consortium, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini JL, McCarthy S, McVean GA, Abecasis GR. A global reference for human genetic variation. Nature. 2015 Oct 1;526(7571):68-74. doi: 10.1038/nature15393.</citation>
    <PMID>26432245</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 22, 2020</study_first_submitted>
  <study_first_submitted_qc>January 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2020</study_first_posted>
  <last_update_submitted>January 28, 2020</last_update_submitted>
  <last_update_submitted_qc>January 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

